Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management

Gelesis announced that the United States Food and Drug Administration cleared the biotechnology company’s lead product candidate Plenity (Gelesis100) as an aid in weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.

Read More »

Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug

Amgen Inc. said a U.S. jury confirmed the validity of patents on the biotech company’s cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc. and Sanofi SA.

Read More »

Push-up capacity may predict men’s heart disease risk

The number of push-ups a man can do in the doctor’s office may be a good predictor of his risk of developing heart disease in the coming years, new research suggests.

Read More »

Sanofi and Regeneron cutting list price of cholesterol drug by 60 percent

Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.

Read More »

Statins may help prevent diabetes-related eye problems

Diabetic patients who take statins to treat high cholesterol may get an added benefit: a lower risk of damage to the retina, a new study suggests.

Read More »

U.S. top court rejects Amgen over cholesterol medication patent fight

The U.S. Supreme Court declined to take up Amgen Inc.’s bid to reinstate a jury verdict the company won against rivals Regeneron Pharmaceuticals Inc. and Sanofi SA in a patent dispute over the cholesterol medication Praluent.

Read More »

New drug options, risk factors added to U.S. heart guidelines

Updated U.S. guidelines on heart health advise more personalized assessment of risk as well as two newer types of cholesterol-lowering drugs for people at particularly high risk of heart attack or stroke.

Read More »

Amgen cuts price of cholesterol drug Repatha

Amgen Inc., looking to boost use of the U.S. biotechnology company’s potent cholesterol drug Repatha, cut the medication’s U.S. list price by 60 percent to $5,850.

Read More »

AstraZeneca digs deeper into cancer with Innate stake

AstraZeneca is plowing deeper into cancer immunotherapy through a wide-ranging deal with Innate Pharma, which includes the British group buying a 9.8 percent stake in the French biotech company.

Read More »

Australian watchdog’s appeal against Pfizer ruling dismissed by court

Australia’s competition watchdog said the High Court dismissed its special leave application to appeal a court’s decision on whether Pfizer Inc.’s local unit used the company’s market power to limit competition for the cholesterol-lowering drug Lipitor.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom